Whole blood interferon‐γ levels predict the therapeutic effects of adoptive T‐cell therapy in patients with advanced pancreatic cancer
-
- Takeshi Ishikawa
- Department of Molecular Gastroenterology and Hepatology Graduate School of Medical Science, Kyoto Prefectural University of Medicine Kyoto Japan
-
- Satoshi Kokura
- Department of Molecular Gastroenterology and Hepatology Graduate School of Medical Science, Kyoto Prefectural University of Medicine Kyoto Japan
-
- Naoyuki Sakamoto
- Iseikai Hyakumanben Clinic Kyoto Japan
-
- Tetsuya Okayama
- Department of Molecular Gastroenterology and Hepatology Graduate School of Medical Science, Kyoto Prefectural University of Medicine Kyoto Japan
-
- Masahiro Endo
- Iseikai Hyakumanben Clinic Kyoto Japan
-
- Reiko Tsuchiya
- Department of Molecular Gastroenterology and Hepatology Graduate School of Medical Science, Kyoto Prefectural University of Medicine Kyoto Japan
-
- Manabu Okajima
- Department of Molecular Gastroenterology and Hepatology Graduate School of Medical Science, Kyoto Prefectural University of Medicine Kyoto Japan
-
- Tatsuzo Matsuyama
- Department of Molecular Gastroenterology and Hepatology Graduate School of Medical Science, Kyoto Prefectural University of Medicine Kyoto Japan
-
- Satoko Adachi
- Department of Cancer ImmunoCell Regulation Graduate School of Medical Science, Kyoto Prefectural University of Medicine Kyoto Japan
-
- Kazuhiro Kamada
- Department of Molecular Gastroenterology and Hepatology Graduate School of Medical Science, Kyoto Prefectural University of Medicine Kyoto Japan
-
- Kazuhiro Katada
- Department of Molecular Gastroenterology and Hepatology Graduate School of Medical Science, Kyoto Prefectural University of Medicine Kyoto Japan
-
- Kazuhiko Uchiyama
- Department of Molecular Gastroenterology and Hepatology Graduate School of Medical Science, Kyoto Prefectural University of Medicine Kyoto Japan
-
- Osamu Handa
- Department of Molecular Gastroenterology and Hepatology Graduate School of Medical Science, Kyoto Prefectural University of Medicine Kyoto Japan
-
- Tomohisa Takagi
- Department of Molecular Gastroenterology and Hepatology Graduate School of Medical Science, Kyoto Prefectural University of Medicine Kyoto Japan
-
- Nobuaki Yagi
- Department of Molecular Gastroenterology and Hepatology Graduate School of Medical Science, Kyoto Prefectural University of Medicine Kyoto Japan
-
- Takashi Ando
- Department of Molecular Gastroenterology and Hepatology Graduate School of Medical Science, Kyoto Prefectural University of Medicine Kyoto Japan
-
- Kazuko Uno
- Louis Pasteur Center for Medical Research Kyoto Japan
-
- Yuji Naito
- Department of Molecular Gastroenterology and Hepatology Graduate School of Medical Science, Kyoto Prefectural University of Medicine Kyoto Japan
-
- Toshikazu Yoshikawa
- Department of Cancer ImmunoCell Regulation Graduate School of Medical Science, Kyoto Prefectural University of Medicine Kyoto Japan
書誌事項
- 公開日
- 2013-03-29
- 資源種別
- journal article
- 権利情報
-
- http://onlinelibrary.wiley.com/termsAndConditions#vor
- DOI
-
- 10.1002/ijc.28117
- 公開者
- Wiley
この論文をさがす
説明
<jats:p>A core challenge in administering immune‐based treatments for cancer is the establishment of easily accessible immunological assays that can predict patients' clinical responses to immunotherapy. In this study, our aim was to predict the therapeutic effects of adoptive T‐cell therapy in patients with advanced pancreatic cancer. To do this, we evaluated whole blood cytokine levels and peripheral regulatory T cells (Tregs) in 46 patients with unresectable or recurrent pancreatic cancer who received adoptive T‐cell therapy at 2‐week intervals. To test immune function, venous blood was obtained from patients before the start of therapy and 2 weeks after the 4th treatment. Whole blood interferon (IFN)‐α levels (after stimulation with the Sendai virus) were evaluated, as well as the levels of 9 cytokines stimulated with phytohemagglutinin [interleukin (IL)−2, IL‐4, IL‐5, IL‐10, IL‐12(p70), IL‐13, tumor necrosis factor‐α, IFN‐γ, and granulocyte‐monocyte colony‐stimulating factor]. Peripheral Tregs were analyzed by flow cytometry. Using the obtained data, we then observed the relationship between these immunological parameters and clinical outcome of patients. We found that the whole blood production of IFN‐γ, IL‐2, IL‐4, IL‐5 and IL‐13 significantly increased after adoptive T‐cell therapy, whereas the number of peripheral Tregs did not change. Multivariate Cox proportional hazards analyses indicated that the number of peripheral Tregs before receiving adoptive T‐cell therapy and the change in IFN‐γ levels after adoptive T‐cell therapy were independent variables predicting overall survival. The findings of this study indicate that the assay of whole blood IFN‐γ production offers promise for evaluating the clinical response of patients to cancer immunotherapy.</jats:p>
収録刊行物
-
- International Journal of Cancer
-
International Journal of Cancer 133 (5), 1119-1125, 2013-03-29
Wiley